Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for MYC-Pathway and Synthetic Lethality Drug Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MGA drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MGA bHLH-ZIP Domain Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. |
View MGA Products |
| Gene Delivery | MGA Promise-ORF / Lentivirus Full-length ORF for stable cell lines and synthetic lethality screening. |
View MGA Products |
| Benchmark Ab | Anti-MGA Recombinant Antibody Recombinant positive control for Western Blot and IP. |
View MGA Products |
| Validator | MGA siRNA Set For knockdown verification in functional assays. |
View MGA Products |
| Related Target A | MAX Obligate heterodimerization partner for MGA and MYC; critical for competitive binding assays. |
View MAX Products |
| Related Target B | MYC Oncogenic transcription factor antagonized by the MGA/MAX complex. |
View MYC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Large molecular weight (~300 kDa) limits full-length protein expression | Truncated functional domains (bHLH-ZIP / T-domain) optimized for solubility and purity (>95%) |
| Validation of competitive binding with MYC/MAX | Highly active MAX recombinant partner proteins available with verified sequences |
| Lack of Controls | Clinical Benchmark Antibodies and sequence-verified reference clones included |
| False Positives in Phenotypic Screens | Validated siRNA pooling strategy included for target specificity verification |
Live MGA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MGA therapeutics is intensifying, with major players shifting focus from traditional transcription factor inhibition to synthetic lethality and targeted protein degradation (TPD). As first-generation MYC-pathway therapies reach the clinic, the next wave of R&D is targeting MGA-deficient tumors through epigenetic vulnerabilities and protein-protein interaction (PPI) modulators.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Modulator) | Academic/Biotech Consortia | Lung Adenocarcinoma, Colorectal Cancer | MGA-MAX Binding Assay (Requires high-purity, sequence-verified bHLH-ZIP domain) |
| Synthetic Lethality (EZH2/PRC2 Inhibitors) | Epizyme, Novartis | MGA-Deficient Solid Tumors | Lentivirus for MGA Knockdown (Need reliable cell line construction for screening) |
| Gene Therapy / mRNA | Preclinical Startups | SCLC, Hematological Malignancies | Functional validation of restored MGA expression (Requires sequence-verified ORF clones) |